January 19, 2026

By:Andrew DeMillo   January 15, 2026  Arkansas Advocate

A nursing home owner who was pardoned by President Donald Trump has been paroled in Arkansas, less than a month after he was ordered to a state prison.

Joseph Schwartz was granted parole by the Arkansas Post Prison Transfer Board, according to an email sent Thursday by a notification system that tells the public about an offender’s change in status. 

January 19, 2026

The Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) has named four new members and one returning member to its Board of Advisors.

The new members, who will serve three three-year terms that run through May 2034, are Anna Lee Powell, Bobbi McDaniel, Denny Sumpter, and Mary Ashleigh Harper. Ray Dillon rejoins the board after serving from 2014 to 2024. These five individuals will join the 32-member board, led by Hatim Smouni, who serves as the board’s chair.

January 12, 2026

The University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has fully implemented the Advarra OnCore Clinical Trials Management System, a major investment that strengthens oversight, efficiency, and growth of cancer clinical trials.

January 12, 2026

Today, at 9:30 a.m., Arkansas Children’s and the Arkansas Attorney General’s Office will host a topping out ceremony to mark progress and the placement of the final beam for the National Center for Opioid Research & Clinical Effectiveness (NCOR).

NCOR will be a first-of-its-kind center dedicated to understanding the effects of the opioid crisis and other substance misuse on the fetus, newborns, developing children and adolescents, as well as pregnant and parenting individuals.

January 12, 2026

Baptist Health is participating in the INNOVATE Trial evaluating the safety and effectiveness of the BrioVAD® Left Ventricular Assist System (LVAS).

The BrioVAD® System, developed by BrioHealth Solutions, Inc., is an advanced left ventricular assist device (LVAD) that is smaller than the only currently FDA approved LVAD available in the U.S. It is designed to reduce complications in patients requiring LVAD support for advanced heart failure.